Raymond James Financial Services Advisors Inc. Takes $217,000 Position in Halyard Health, Inc. (HYH)

Raymond James Financial Services Advisors Inc. bought a new stake in Halyard Health, Inc. (NYSE:HYH) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 5,537 shares of the medical instruments supplier’s stock, valued at approximately $217,000.

A number of other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. raised its position in Halyard Health by 6,362.1% in the 1st quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock valued at $226,229,000 after buying an additional 5,847,442 shares during the last quarter. Vanguard Group Inc. raised its position in Halyard Health by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock valued at $165,711,000 after buying an additional 196,367 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Halyard Health by 19.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,133,049 shares of the medical instruments supplier’s stock valued at $123,067,000 after buying an additional 507,893 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Halyard Health by 242.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,864,646 shares of the medical instruments supplier’s stock valued at $73,244,000 after buying an additional 1,320,735 shares during the last quarter. Finally, State Street Corp raised its position in Halyard Health by 7.5% in the 2nd quarter. State Street Corp now owns 1,702,423 shares of the medical instruments supplier’s stock valued at $66,872,000 after buying an additional 119,154 shares during the last quarter. 91.73% of the stock is currently owned by institutional investors and hedge funds.

Halyard Health, Inc. (NYSE:HYH) opened at $45.45 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.19 and a current ratio of 2.13. Halyard Health, Inc. has a one year low of $33.16 and a one year high of $50.99. The company has a market capitalization of $2,128.72, a P/E ratio of 21.75, a PEG ratio of 2.46 and a beta of 1.69.

Halyard Health (NYSE:HYH) last issued its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.13. Halyard Health had a return on equity of 8.65% and a net margin of 3.52%. The company had revenue of $401.40 million during the quarter, compared to the consensus estimate of $394.54 million. During the same period in the previous year, the company posted $0.48 EPS. The firm’s revenue for the quarter was up 1.0% compared to the same quarter last year. research analysts anticipate that Halyard Health, Inc. will post 2.08 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Raymond James Financial Services Advisors Inc. Takes $217,000 Position in Halyard Health, Inc. (HYH)” was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://transcriptdaily.com/2017/11/13/raymond-james-financial-services-advisors-inc-takes-217000-position-in-halyard-health-inc-hyh.html.

A number of equities research analysts recently issued reports on HYH shares. Stifel Nicolaus reissued a “buy” rating and issued a $45.00 target price on shares of Halyard Health in a research report on Thursday, September 21st. BidaskClub raised Halyard Health from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. Deutsche Bank AG boosted their price target on Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. ValuEngine raised Halyard Health from a “hold” rating to a “buy” rating in a research report on Saturday, November 4th. Finally, TheStreet lowered Halyard Health from a “b-” rating to a “c+” rating in a research report on Monday, October 30th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $44.00.

Halyard Health Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Institutional Ownership by Quarter for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply